APOB and diabetes mellitus: With respect to LDL-C and non-LDL-C therapeutic targets, a recent joint Consensus Statement (American Diabetes Association and American College of Cardiology Foundation) suggests new treatment goals for apoB in patients with atherogenic dyslipidemia and cardiometabolic risk.